Home » Stocks » USRM

U.S. Stem Cell, Inc. (USRM)

Stock Price: $0.0325 USD -0.0030 (-7.14%)
Updated Jan 27, 2021 3:57 PM EST - Market closed
Market Cap 14.25M
Revenue (ttm) 4.43M
Net Income (ttm) -3.60M
Shares Out 396.64M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $0.0325
Previous Close $0.0350
Change ($) -0.0030
Change (%) -7.14%
Day's Open 0.0398
Day's Range 0.0320 - 0.0401
Day's Volume 4,817,612
52-Week Range 0.003 - 0.048

News

There are no news available yet.

About USRM

U.S. Stem Cell, a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2008
CEO
Mike Tomas
Employees
10
Stock Exchange
OTCMKTS
Ticker Symbol
USRM
Full Company Profile

Financial Performance

In 2018, U.S. Stem Cell's revenue was $6.70 million, an increase of 21.38% compared to the previous year's $5.52 million. Losses were -$2.16 million, -37.95% less than in 2017.

Financial Statements